Narrative review / 2014
A review highlights the role of inflammation in mood disorders and points to improved outcomes when anti-inflammatory agents are used as adjuncts.
This review examined evidence linking inflammation to mood disorders, potential mechanisms, and novel anti-inflammatory therapeutic options. Elevated levels of pro-inflammatory cytokines have been repeatedly demonstrated in patients with major depressive disorder and bipolar disorder, and inducing a pro-inflammatory state induces depressive-like sickness behavior. Anti-inflammatory agents being investigated include acetyl-salicylic acid, celecoxib, anti-TNF-α agents, minocycline, curcumin, and omega-3 fatty acids. Current evidence indicates improved outcomes in mood disorder patients when anti-inflammatory agents are used as an adjunct to conventional therapy, though more research is required to determine therapeutic benefit and dosage.
- Study type
- Narrative review
- Who was studied
- Patients with mood disorders (MDD and BD) and healthy or medically ill subjects
- What was measured
- Association between inflammation and mood disorders, mechanisms, and therapeutics
THE PAPER
Inflamed moods: a review of the interactions between inflammation and mood disorders.
Rosenblat JD, Cha DS, Mansur RB, McIntyre RS. Prog Neuropsychopharmacol Biol Psychiatry, 2014.
This note is written from the study's published abstract. It summarizes what the authors reported; it is not medical advice and does not replace reading the full paper.